MAB
Mabion GPW LISTED

Contracts

All Active Completed

source: current reports (ESPI/EBI) · incomplete data — not every contract is disclosed · 12 contracts in the database

DISCLOSED VALUE 12M
145 k USD
1 of 5 contracts
SHARE OF REVENUE 12M
—
currency other than PLN
LARGEST COUNTERPARTY
100%
Novavax, Inc.
LONGEST TERM
4 years
until 2029
Ongoing

Instituto de Biologia Molecular do Paraná (IBMP, Brazylia)

19 m PLN

Nowa · Umowa ramowa i SOW#1: rozwój linii komórkowej i procesu, materiał do badań klinicznych

Umowa ramowa i SOW#1: rozwój linii komórkowej i procesu, materiał do badań klinicznych

Status

Ongoing

Signing date

April 13, 2025

Term

—

Report FY 2025

Ongoing

Novalgen Ltd (Wielka Brytania)

5.6 m PLN

Stan realizacji · Transfer metod, seria inżynieryjna i GMP, badania stabilności DS i DP · until 2027

Transfer metod, seria inżynieryjna i GMP, badania stabilności DS i DP

Status

Ongoing

Signing date

August 16, 2024

Term

September 30, 2027

Report FY 2025

SHOWING 11–12 OF 12
Page 2 / 2 ← →

Portfolio summary

Contracts
12
Active
9
Total value
27.5 m PLN
Average value
6.9 m PLN
Since
August 16, 2024

Where this data comes from

Contracts come from current reports (ESPI/EBI) — the company discloses only those exceeding its materiality threshold. The list is by definition incomplete.

Status — inferred from the event type and the term's end date, not a dedicated source field.

Share of revenue 12M — only when both the contracts' dominant currency and the company's reporting currency are PLN, with no currency conversion.